An imaging approach that can predict chemotherapy efficacy
Being able to predict the response of patients to chemotherapy would undoubtedly be beneficial for patient well-being, avoiding the unnecessary toxic side effects. The metabolites phosphoethanolamine (PE) and glycerophosphocholine (GPC) are involved in cell membrane metabolism, and the PE to GPC ratio goes up during malignant transformation of cells. The EU-funded MIRACLE project aims to validate this ratio as a biomarker of predicting cancer treatment response. Scientists will assess these phospholipid biomarkers in patients in a non-invasive manner using MRI under different field strengths. The results of the study have the potential to bring the approach a step closer to regulatory clearance for clinical use.
Fields of science
Call for proposalSee other projects for this call
Funding SchemeCSA - Coordination and support action
55455 2070 Minneapolis Mn
See on map
3584 CH Utrecht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.